| Phase 3 | Streptococcus Pneumoniae | - |
| Phase 3 | Diabetes Mellitus, Type 2 | - |
| Phase 3 | Hypercholesterolemia | - |
| Phase 3 | Relapsing Multiple Sclerosis | - |
| Phase 3 | Relapsing Multiple Sclerosis | - |
| Phase 3 | Sickle Cell Disease | - |
| Phase 3 | Type 2 Diabetes | - |
| Phase 3 | Maintenance of Smoking Cessation | - |
| Phase 3 | Breast Neoplasms | - |
| Phase 3 | Metabolic Syndrome | - |
| Phase 3 | Plasma Cell Myeloma | - |
MenACYW conjugate vaccine | Phase 3 | Meningitis, Meningococcal | - |
| Phase 3 | Asthma | - |
| Phase 3 | Type 2 Diabetes Mellitus | - |
SR34006 (idraparinux sodium) Injection | Phase 3 | Atrial Fibrillation | - |
| Phase 3 | Diabetes Mellitus | - |
SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent D614) (primary series) | Phase 3 | COVID-19 | - |
| Phase 3 | Prostatic Neoplasms | - |
| Phase 3 | Atrial Fibrillation | - |
| Phase 3 | Chronic Rhinosinusitis With Nasal Polyps | - |
Doxorubicine + docetaxel sequential | Phase 3 | Breast Neoplasms | - |
| Phase 3 | Constipation | - |
Fabrazyme (agalsidase beta) | Phase 3 | Fabry Disease | - |
| Phase 3 | Colorectal Neoplasms | - |
FluCAM [Fludara + Campath] | Phase 3 | B-Cell Chronic Lymphocytic Leukemia | - |
| Phase 3 | Hygiene | - |
Saredutant succinate (SR48968C) | Phase 3 | Depressive Disorder | - |
| Phase 3 | Venous Thromboembolism | - |
| Phase 3 | Diabetes Mellitus, Type 2 | - |
| Phase 3 | Rheumatoid Arthritis | - |
paracetamol 4.8% paediatric oral suspension | Phase 3 | Fever | - |
DTaP-HB PRP~T Combined Vaccine | Phase 3 | Diphtheria | - |
Lactic Acid (Dermacyd PH_DETINBACK Tangerine Mix) | Phase 3 | Hygiene | - |
| Phase 3 | Type 2 Diabetes Mellitus | - |
DOCETAXEL(XRP6976) + MODAFINIL | Phase 3 | Prostatic Neoplasms | - |
Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine | Phase 3 | Meningococcal Immunization | - |
Lantus (insulin glargine [rDNA origin] injection) | Phase 3 | Diabetes Mellitus | - |
Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower | Phase 3 | Hygiene | - |
Insulin glargine U300 (new formulation of insulin glargine) HOE901 | Phase 3 | Diabetes Mellitus Type 2 | - |
| Phase 3 | Influenza | - |
ALIROCUMAB SAR236553 (REGN727) | Phase 3 | Hypercholesterolemia | - |
| Phase 3 | Arteriosclerosis | - |
| Phase 3 | Hygiene | - |
Insulin glargine new formulation (HOE901) | Phase 3 | Type 1 Diabetes Mellitus | - |
Hexaxim®: DTaP-IPV-HB-PRP-T Combined Vaccine | Phase 3 | Diphtheria | - |
| Phase 3 | Lung Transplant Rejection | - |
DTaP-IPV-HB-PRP~T vaccine | Phase 3 | Diphtheria | - |
Lactic Acid (Dermacyd PH_DETINLYN Tangerine Mix) | Phase 3 | Hygiene | - |
Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) | Phase 3 | Carcinoma | - |
| Phase 3 | Anxiety Disorders | - |
| Phase 3 | Rheumatoid Arthritis | - |
| Phase 3 | Chronic Rhinosinusitis Without Nasal Polyps | - |
Thiocolchicoside+Ketoprofen | Phase 3 | Low Back Pain | - |
| Phase 3 | Arthroplasty, Replacement, Hip | - |
| Phase 2 | Nasopharyngeal Neoplasms | - |
Monovalent Subvirion A/H1N1 Influenza vaccine | Phase 2 | Influenza | - |
Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®) | Phase 2 | Meningitis | - |
| Phase 2 | Diffuse Large B-Cell Lymphoma | - |
Meningococcal Polysaccharide Diphtheria Toxoid Conjugate | Phase 2 | Meningitis | - |
docetaxel and carboplatin | Phase 2 | Lung Neoplasms | - |
| Phase 2 | Plasmodium Falciparum Infection | - |
Inactivated Poliomyelitis vaccine (IMOVAX) | Phase 2 | Poliomyelitis | - |
| Phase 2 | Rheumatoid Arthritis | - |
| Phase 2 | Therapy, Prostatic Neoplasms | - |
sevelamer carbonate, sevelamer hydrochloride | Phase 2 | Chronic Kidney Disease | - |
Polysaccharide Diphtheria Toxoid Conjugate Vaccine | Phase 2 | Meningococcal Meningitis | - |
| Phase 2 | Hyperphosphatemia | - |
| Phase 2 | Joint Disease | - |
| Phase 2 | Rheumatoid Arthritis | - |
| Phase 2 | Non-small Cell Lung Cancer | - |
| Phase 2 | Hypercholesterolemia | - |
A/H5N1 inactivated, split-virion influenza virus | Phase 2 | Influenza | - |
| Phase 2 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | - |
Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1 | Phase 2 | Influenza | - |
Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine | Phase 2 | Meningitis | - |
A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine | Phase 2 | Influenza | - |
| Phase 2 | Myelodysplastic Syndromes | - |
Long term follow up in all patients who received SAR422459 in previous study TDU13583 | Phase 2 | Stargardt's Disease | - |
| Phase 2 | Sphingomyelin Lipidosis | - |
| Phase 2 | Alzheimer Disease | - |
| Phase 2 | Neoplasm | - |
| Phase 2 | Pain | - |
| Phase 2 | Acquired Thrombotic Thrombocytopenic Purpura | - |
| Phase 2 | Depressive Disorder | - |
| Phase 2 | Asthma | - |
| Phase 2 | Hidradenitis Suppurativa | - |
Pneumococcal Conjugate Vaccine formulation 1 | Phase 2 | Pneumococcal Immunisation | - |
| Phase 2 | Influenza | - |
| Phase 2 | Breast Neoplasms | - |
| Phase 2 | Type 1 Diabetes Mellitus | - |
